SCHEMBL5135362

SCHEMBL5135362

CCCCn1c(CN(CCCC2CCCCC2)Cc2ccc3c(c2)OCO3)cnc1-c1cccc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
F2R P25116 4/20 0.42
UBE2M P61081 3/20 0.36
DCUN1D1 Q96GG9 3/20 0.36
CTSL P07711 3/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KMT2A Q03164 1/20 0.34
USP2 O75604 1/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135260 0.96 C5AR1 (0.44) C5AR1F2RUBE2MDCUN1D1CTSL
SCHEMBL5135372 0.92 C5AR1 (0.44) C5AR1F2RUBE2MDCUN1D1CTSL
SCHEMBL5136483 0.92 C5AR1 (0.43) C5AR1F2RUBE2MDCUN1D1CTSL
SCHEMBL4772930 0.91 C5AR1 (0.52) C5AR1F2RUBE2MDCUN1D1CTSL
SCHEMBL5136963 0.89 C5AR1 (0.47) C5AR1F2RHTR2AHTR2CHTR2B
SCHEMBL4768999 0.89 C5AR1 (0.51) C5AR1F2RUBE2MDCUN1D1CTSL
SCHEMBL5135679 0.88 C5AR1 (0.43) C5AR1F2RUBE2MDCUN1D1CTSL
SCHEMBL5135654 0.88 C5AR1 (0.52) C5AR1F2RHSP90AA1HSP90AB1LMNA
SCHEMBL5135194 0.87 C5AR1 (0.44) C5AR1F2RUBE2MDCUN1D1CTSL
SCHEMBL4763676 0.87 C5AR1 (0.53) C5AR1F2RUBE2MDCUN1D1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed